argenx

ARGX

Market cap $50.2B

Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART's potential to treat broad set of myasthenia gravis patients Real-world evidence and long-term data reinforce VYVGART's sustained impact on patient outcomes More than 40 abstracts across MG, CIDP, MMN, and IIM highlight depth of clinical evidence and ongoing commitment to rare neuromuscular disease communities October 15, 2025, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) and pipeline candidate empasiprubart at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session in San Francisco from October 29-November 1, 2025. “We're proud to have a robust presence at this year's AANEM Annual Meeting and MGFA Scientific Session, where we are sharing pivotal data and meaningful evidence across a broad spectrum of serious neuromuscular diseases, including MG, CIDP, MMN and IIM,” said Luc Truyen, M.D.

October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of shareholders will be held at 14:00 CET on Tuesday, November 18, 2025 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands. The shareholders and all other persons with meeting rights are invited to attend the Extraordinary General Meeting of shareholders.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

President Donald Trump delivered the pharmaceutical industry another blow this week, threatening 100% tariffs on some companies.

Here is how argenex SE (ARGX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a significant expansion of its global partnership with argenx SE, a global immunology company. As part of the expanded agreement, FUJIFILM Biotechnologies will initiate manufacturing of argenx' drug substance for efgartigimod at the Holly Springs, North Carolina, site in 2028. argenx is the first anno.

argenx SE - Special Call Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Roeland Vanhauwaert Peter Ulrichts - Chief Scientific Officer Luc Truyen - Chief Medical Officer Rebecca Shilling Jeff Guptill Tim Van Hauwermeiren - Co-Founder, CEO & Executive Director Conference Call Participants Steven Burden Ricardo Maselli Danielle Brill Bongero - Truist Securities, Inc., Research Division Yaron Werber - TD Cowen, Research Division Ricardo Maselli, M.D. Leland Gershell - Oppenheimer & Co. Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Patrick Culliton - Stifel, Nicolaus & Company, Incorporated, Research Division Maddalena Delma Caiati - Guggenheim Securities, LLC, Research Division Presentation Beth DelGiacco VP and Global Head of Corporate Communications & Investor Relations Good afternoon.

argenx's blockbuster Vyvgart drives rapid growth, but heavy reliance on one product and US sales creates concentration risk. The company's robust R&D investment and Immunology Innovation Program fuel a strong pipeline, with empasiprubart showing promising diversification potential. Risks include intense competition, potential loss of exclusivity, and US pricing policy changes, but argenx's large cash reserves provide a solid runway.

argenx SE (NASDAQ:ARGX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Karl Gubitz - Chief Financial Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning. Welcome to Morgan Stanley's Global Healthcare Conference.

Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.